Lipitor and Protein-losing gastroenteropathy - a phase IV clinical study of FDA data


Protein-losing gastroenteropathy is reported only by a few people who take Lipitor.

The phase IV clinical study analyzes which people take Lipitor and have Protein-losing gastroenteropathy. It is created by eHealthMe based on reports of 239,728 people who have side effects while taking Lipitor from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 29, 2022

239,728 people reported to have side effects when taking Lipitor.
Among them, 4 people (0.0%) have Protein-losing gastroenteropathy.

What is Lipitor?

Lipitor has active ingredients of atorvastatin calcium. It is often used in high blood cholesterol. eHealthMe is studying from 247,286 Lipitor users for its effectiveness, alternative drugs and more.

What is Protein-losing gastroenteropathy?

Protein-losing gastroenteropathy (gastrointestinal tract that results in a net loss of protein from the body) is found to be associated with 236 drugs and 192 conditions by eHealthMe.

Number of Lipitor and Protein-losing gastroenteropathy reports submitted per year:

Could Lipitor cause Protein-losing gastroenteropathy?

Gender of people who have Protein-losing gastroenteropathy when taking Lipitor *:

  • female: 0.0 %
  • male: 100 %

Age of people who have Protein-losing gastroenteropathy when taking Lipitor *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 100 %

Common drugs people take besides Lipitor *:

  1. Lasix: 2 people, 50.00%
  2. Fosrenol: 2 people, 50.00%
  3. Diovan: 2 people, 50.00%
  4. Zocor: 1 person, 25.00%
  5. Symbicort: 1 person, 25.00%
  6. Spironolactone: 1 person, 25.00%
  7. Sabril: 1 person, 25.00%
  8. Nasonex: 1 person, 25.00%
  9. Metoclopramide: 1 person, 25.00%
  10. Loratadine: 1 person, 25.00%

Common side effects people have besides Protein-losing gastroenteropathy *:

  1. Nausea (feeling of having an urge to vomit): 2 people, 50.00%
  2. Malabsorption (a state arising from abnormality in absorption of food nutrients across the gastrointestinal (gi) tract): 2 people, 50.00%
  3. Diarrhea: 2 people, 50.00%
  4. Dehydration (dryness resulting from the removal of water): 2 people, 50.00%
  5. Nutritional Condition Abnormal: 1 person, 25.00%
  6. Lymphangiectasia (a disease of the lymphatic vessels that results in the leakage of protein-rich lymph): 1 person, 25.00%
  7. Immunodeficiency: 1 person, 25.00%
  8. Hypoalbuminaemia (levels of albumin in blood serum are abnormally low): 1 person, 25.00%
  9. Breathing Difficulty: 1 person, 25.00%
  10. Adverse Event: 1 person, 25.00%

Common conditions people have *:

  1. Cardiac Failure: 2 people, 50.00%
  2. Infantile Spasms: 1 person, 25.00%
  3. Coronary Heart Disease (narrowing or blockage of the coronary arteries): 1 person, 25.00%
  4. Ascites (accumulation of fluid in the abdominal cavity): 1 person, 25.00%

* Approximation only. Some reports may have incomplete information.

Do you take Lipitor and have Protein-losing gastroenteropathy?

Check whether Protein-losing gastroenteropathy is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Related studies

How severe was Protein-losing gastroenteropathy and when was it recovered:

Expand to all the drugs that have ingredients of atorvastatin calcium:

Alternative drugs to, pros and cons of Lipitor:

Common Lipitor side effects:

Browse all side effects of Lipitor:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Protein-losing gastroenteropathy treatments and more:

COVID vaccines that are related to Protein-losing gastroenteropathy:

All the drugs that are associated with Protein-losing gastroenteropathy:

All the conditions that are associated with Protein-losing gastroenteropathy:

How the study uses the data?

The study uses data from the FDA. It is based on atorvastatin calcium (the active ingredients of Lipitor) and Lipitor (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: